5,7-Dichlorokynurenic acid sodium saltCAS# 1184986-70-6 |
- Verteporfin
Catalog No.:BCC3690
CAS No.:129497-78-5
- Miglustat hydrochloride
Catalog No.:BCC5186
CAS No.:210110-90-0
- Hydrochlorothiazide
Catalog No.:BCC4786
CAS No.:58-93-5
- Miglustat
Catalog No.:BCC5187
CAS No.:72599-27-0
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1184986-70-6 | SDF | Download SDF |
| PubChem ID | 44134672 | Appearance | Powder |
| Formula | C10H4Cl2NNaO3 | M.Wt | 280.04 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in 1eq. NaOH | ||
| Chemical Name | sodium;5,7-dichloro-4-oxo-1H-quinoline-2-carboxylate | ||
| SMILES | C1=C(C=C2C(=C1Cl)C(=O)C=C(N2)C(=O)[O-])Cl.[Na+] | ||
| Standard InChIKey | VPRPMJHKWHCUFW-UHFFFAOYSA-M | ||
| Standard InChI | InChI=1S/C10H5Cl2NO3.Na/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14;/h1-3H,(H,13,14)(H,15,16);/q;+1/p-1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Sodium salt of 5,7-Dichlorokynurenic acid, a potent antagonist at the glycine site of the NMDA receptor (Ki = 79 nM vs. [3H]-glycine). |
5,7-Dichlorokynurenic acid sodium salt Dilution Calculator
5,7-Dichlorokynurenic acid sodium salt Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5709 mL | 17.8546 mL | 35.7092 mL | 71.4184 mL | 89.273 mL |
| 5 mM | 0.7142 mL | 3.5709 mL | 7.1418 mL | 14.2837 mL | 17.8546 mL |
| 10 mM | 0.3571 mL | 1.7855 mL | 3.5709 mL | 7.1418 mL | 8.9273 mL |
| 50 mM | 0.0714 mL | 0.3571 mL | 0.7142 mL | 1.4284 mL | 1.7855 mL |
| 100 mM | 0.0357 mL | 0.1785 mL | 0.3571 mL | 0.7142 mL | 0.8927 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fmoc-D-Tyr(tBu)-OH
Catalog No.:BCC3569
CAS No.:118488-18-9
- Cyclo(L-Phe-trans-4-hydroxy-L-Pro)
Catalog No.:BCN3989
CAS No.:118477-06-8
- Arcyriaflavin A
Catalog No.:BCC7370
CAS No.:118458-54-1
- Licoricesaponin G2
Catalog No.:BCN7897
CAS No.:118441-84-2
- MK 886
Catalog No.:BCC7017
CAS No.:118414-82-7
- nTZDpa
Catalog No.:BCC7268
CAS No.:118414-59-8
- UNC 926 hydrochloride
Catalog No.:BCC2445
CAS No.:1184136-10-4
- AG-18
Catalog No.:BCC1051
CAS No.:118409-57-7
- Trimethylamine oxide
Catalog No.:BCN1819
CAS No.:1184-78-7
- Australine
Catalog No.:BCN2053
CAS No.:118396-02-4
- Licoricesaponin A3
Catalog No.:BCN7905
CAS No.:118325-22-7
- Tazarotene
Catalog No.:BCC2540
CAS No.:118292-40-3
- TRIS hydrochloride
Catalog No.:BCC7589
CAS No.:1185-53-1
- Myelin Basic Protein (87-99)
Catalog No.:BCC1028
CAS No.:118506-26-6
- LP 12 hydrochloride
Catalog No.:BCC7517
CAS No.:1185136-22-4
- DPPE fumarate
Catalog No.:BCC5669
CAS No.:1185241-83-1
- Sagittatoside A
Catalog No.:BCN2285
CAS No.:118525-35-2
- Sagittatoside B
Catalog No.:BCN2357
CAS No.:118525-36-3
- Sagittatoside C
Catalog No.:BCN3059
CAS No.:118525-37-4
- Icaritin
Catalog No.:BCN5352
CAS No.:118525-40-9
- Baohuoside V
Catalog No.:BCN2887
CAS No.:118544-18-6
- H-Orn(2-Cl-Z)-OH
Catalog No.:BCC3002
CAS No.:118553-99-4
- Boc-Orn(2-Cl-Z)-OH
Catalog No.:BCC3428
CAS No.:118554-00-0
- Phaseoloidin
Catalog No.:BCN8451
CAS No.:118555-82-1
Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site.[Pubmed:2172769]
Mol Pharmacol. 1990 Oct;38(4):554-61.
5,7-Dichlorokynurenic acid (5,7-DCKA), one of the most potent excitatory amino acid receptor antagonists yet described, binds to a strychnine-insensitive glycine binding site located on the N-methyl-D-aspartate (NMDA) receptor complex (Ki = 79 nM versus [3H]glycine). 5,7-DCKA (10 microM) antagonized the ability of NMDA to stimulate the binding of the radiolabeled ion channel blocker N-[3H][1-(2-thienyl)cyclohexyl]-piperidine ([3]TCP). Glycine was able to overcome this effect and in the presence of 5,7-DCKA enhanced [3H]TCP binding to antagonist-free levels. 5,7-DCKA completely and noncompetitively antagonized several NMDA receptor-mediated biochemical and electrophysiological responses. Thus, micromolar concentrations of 5,7-DCKA inhibited NMDA-stimulated elevation of cytosolic calcium in cultured hippocampal neurons, cGMP accumulation in cerebellar slices, and norepinephrine release from hippocampal slices. The glycine antagonist could also block the action of synaptically released agonist, as shown by its ability to inhibit the increase in the magnitude of the population spike that follows tetanic stimulation of the hippocampus in vitro (long term potentiation). Inclusion of glycine or D-serine prevented all these effects of the antagonist. 5,7-DCKA was a potent anticonvulsant when administered intracerebroventricularly to mice. As in the in vitro experiments, the dose-response curve for the antagonist was shifted rightward in a parallel fashion when D-serine was coinjected. This spectrum of activity displayed by a compound acting at the glycine binding site suggests that the therapeutic utility of glycine antagonists will be similar to those proposed for other types of glutamate receptor antagonists.
